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0o the Editor: Unloading the left ventricle (LV) after ST-segment
levation myocardial infarction (STEMI) in addition to reperfu-
ion therapy may reduce infarct size and may give the myocardium
ime to recuperate from ischemic stunning (1). This may be
articularly true in STEMI patients with cardiogenic shock (CS)
r pre-shock, who have a large ischemic area at risk for necrosis.
owadays, intra-aortic counterpulsation (IABP) is the most ac-
essible method of LV unloading and circulatory support. How-
ver, this treatment modality in randomized trials failed to show
ny benefit on infarct size, LV function, and/or mortality in the
etting of STEMI. Nonetheless, mostly based on nonrandomized
tudies, IABP remains advocated and frequently used for hemo-
ynamic stabilization in CS. True LV unloading with a left
entricular assist device (LVAD) might be superior to IABP
herapy. The Impella LP2.5 (Abiomed Europe GmbH, Aachen,
ermany) is a novel catheter-mounted (9-F) microaxial rotary
lood pump (12-F) able to provide flow up to 2.5 l/min. It is
nserted percutaneously through the femoral artery and positioned
cross the aortic valve in the LV. However, before initiation of a
rial in STEMI patients with hemodynamic instability, the safety
nd feasibility of Impella support should be determined in hemo-
ynamically less compromised patients.
From December 2005 until June 2006, a total of 20 consecutive
atients were included in this single-center, nonrandomized pilot
tudy (the AMC MACH [Academic Medical Center Mechanical
upport for Acute Congestive Heart failure in STEMI patients] 2
tudy), which was designed to evaluate the safety and feasibility of
oncomitant LV unloading with the Impella LP2.5 in STEMI.
ligible were all patients presenting with a first anterior STEMI
ithin 6 h of symptom onset without CS treated with primary
ercutaneous coronary intervention (PCI). Immediately after PCI,
0 patients received 3 days of Impella support (Impella group). A
oncurrent group of 10 patients meeting all eligibility criteria were
reated according to routine care, including IABP therapy as
eemed necessary by the attending operator in 3 patients. All
atients received optimal pharmacotherapy, including aspirin,
eta-blocker, angiotensin-converting enzyme inhibitor, and statin
herapy.
Continuous data are presented as mean  standard deviation.
ifferences in continuous variables were assessed by the Mann-
hitney U test, in categorical variables by the chi-square test, and
n paired comparisons by the Wilcoxon signed-rank test.
The primary safety and feasibility end points included device-
elated complications and major adverse cardiac and cerebral events
uring support and 4-month follow-up. The secondary objective,
V recovery, was assessed by echocardiography in an exploratory gashion to support our hypothesis and provide a more profound
asis for further controlled trials.
Global left ventricular ejection fraction (LVEF) in both groups
as determined on transthoracic echocardiography immediately
fter PCI (baseline), at 3 days (after Impella removal), and after 4
onths. Baseline transthoracic echocardiography also served to
ssess the presence of LV mural thrombus, which is an exclusion
riterion for Impella therapy. Finally, aortic regurgitation was
ssessed before, during, and after Impella support as well as at
-month follow-up. Echocardiographic analyses were performed
y an independent core laboratory (DCRI, Duke University,
urham, North Carolina).
The patient characteristics at first glance show no significant
ifferences between the groups (Table 1). However, in the
mpella group there is a trend toward higher scores on most
onventional risk factors, admission laboratory values, and
ndexes of extent of myocardial necrosis, indicating a worse
linical condition at baseline.
Impella insertion was successful in all cases. Median time for
ump placement was 11 min. After subsequent maximization of
ump performance (maximum flow 2.2  0.1 l/min; mean 
tandard error of the mean), an immediate increase in cardiac
utput (4.4  0.3 l/min to 4.9  0.5 l/min, n  5, p  NS) and
decrease in pulmonary capillary wedge pressure (24.3  2.4 mm
g to 17.3  0.4 mm Hg, n  5, p  0.05) was observed.
eaning was commenced from 48 to 72 h. Median assist time was
1 h and 43 min. During Impella support no signs or increase by
1 grade of aortic regurgitation were observed; neither were any
ate adverse effects on the aortic valve at 4-month follow-up. Groin
leeding requiring transfusion (mainly oozing along femoral
heath) was observed in 4 patients in the Impella group compared
ith 2 in the control group; however, after implementing a more
trict institutional heparin protocol, oozing was not an important
ssue. Hemolysis (free-hemoglobin levels 10 mg/dl) occurred
nly within the first 24 h of support, returning quickly toward
ormal levels. There were no other device-related adverse events,
or major adverse cardiac and cerebral events (death, repeat
yocardial infarction, target vessel revascularization, stroke) dur-
ng and after Impella support.
Changes in LVEF from baseline (immediately after PCI) to
-day (Impella removal) and 4-month follow-up are shown in
igure 1 (vertical bars show mean values  standard error of the
ean for paired data). In the Impella group (n  8), LVEF
mproved from 28% at baseline to 37% (p  0.05) and 41% (p 
.05) after respectively 3 days and 4 months, whereas in the control
roup (n  9) no significant improvement was observed; LVEF
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p  NS).
We previously showed the safety and feasibility of periproce-
ural LV support with the Impella LP2.5 in elective high-risk PCI
atients (2) (the AMC MACH1 study). The presented pilot study
Patient Characteristics in the AMC MACH2 Study
Table 1 Patient Characteristics in the AMC MACH
Variables
Clinical characteristics and risk factors
Age (yrs)
Male gender (%)
Hypertension (%)
Diabetes (%)
Current smoker (%)
Hypercholesterolemia (%)
Stroke (%)
Heart rate (beats/min)
Diastolic pressure (mm Hg)
Systolic pressure (mm Hg)
Admission laboratory values
Serum creatinine (mol/l)
Hemoglobin (mmol/l)
Plasma glucose (mmol/l)
High-sensitivity C-reactive protein (mg/l)
NT-proBNP (ng/l)
CK-MB (g/l)
Treatment-related characteristics
Ischemic time
TIMI flow grade 3 in culprit artery after intervention (
Cardiac markers after PCI
Peak CK-MB (g/l)
CK-MB AUC (g.h/l)
Troponin T AUC (g.h/l)
AMC MACH  Academic Medical Center Mechanical support for Acute
 creatine kinase; NT-proBNP  N-terminal part of the pro-B-type
Thrombolysis In Myocardial Infarction.
Figure 1 Left Ventricular Recovery at Day 3 and 4-MonthFollow-Up After ST-Segment Myocardial Infarction
Changes in left ventricular ejection fraction (LVEF) from baseline to respectively
day 3 (after Impella removal) and 4-month follow-up (FUP) in the Impella group
and the control group.Pn STEMI patients without hemodynamic compromise extends
his safety and feasibility to concomitant LV support during 3 days
ith Impella LP2.5. Severe complications, such as major bleeding,
ascular injury, thromboembolism, and major hemolysis, often
ccompanying miniaturized LVADs, did not occur in our study.
urthermore, the Impella showed to be easily implantable and
rovided an increase of cardiac output and a decrease of LV
nd-diastolic pressure. We previously showed that the Impella
P2.5 improves intracoronary perfusion pressure, coronary flow
elocity reserve, and microvascular resistance (3).
Most interestingly we observed a marked LV recovery in the
mpella group, suggesting a possible beneficial effect of mechanical
nloading on postinfarct adverse remodeling.
The extent of this effect is more than could be expected after
ptimal reperfusion combined with optimal postinfarction phar-
acotherapy. Functional recovery occurs in a significant propor-
ion of patients because of contemporary STEMI treatment.
eported increases in LVEF from baseline within 24 h after PCI
p to 6 months range from 3 LVEF percentage points to 4.5
VEF percentage points, comparable with the improvement
bserved in our control group (4,5). However, this is considerably
ess compared with the 9 LVEF percentage points and 13 LVEF
ercentage points improvement observed after respectively 3 days
nd 4 months in the Impella group.
In conclusion, the findings concerning the safety and feasibility
f prolonged Impella LP2.5 support in the setting of STEMI are
ncouraging. Furthermore, LV unloading resulted in an unex-
ected acute and sustained LV recovery compared with routine-
are patients. These findings should be seen as the first explorative
ndings in humans and an incentive for larger-scale studies.
dy
Impella (n  10) Control (n  10)
58.2 3.5 58.1 3.3
9 (90) 6 (60)
5 (50) 2 (20)
3 (30) 1 (10)
7 (70) 6 (60)
2 (20) 1 (10)
1 (10) 0
81.0 6.0 85.5 6.3
82.8 3.2 73.8 6.7
128.0 4.4 116.4 6.6
69.8 5.5 63.3 4.7
9.1 0.2 8.9 0.3
9.9 1.1 8.7 1.2
34.7 22.0 10.6 6.1
1,619.0 1,200.2 387.3 244.8
49.1 22.5 16.3 6.9
4 h 48 m 54 m 3 h 54 m 47 m
9 (90) 10 (100)
251.3 50.4 214.7 36.5
4,494 851 3,897 633
326 60 203 31
tive Heart Failure in STEMI patients; AUC  area under the curve; CK
retic peptide; PCI  percutaneous coronary intervention; TIMI 2 Stu
%)
Congesercutaneous LVAD therapy may prove to be a promising alter-
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March 11, 2008:1044–8ative for the passive support offered by IABP. We recently
nitiated a head-to-head randomized comparison of IABP and
mpella support in hemodynamically compromised patients with
arge anterior STEMI.
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2001;134:451–8.Letters to the Editorole of Percutaneous Coronary
inimalist Intervention in the
anagement of Acute
T-Segment Elevation
yocardial Infarction
n their interesting study, Sianos et al. (1) investigated the impact
f thrombus burden on the clinical outcome and angiographic
nfarct-related artery (IRA) stent thrombosis in patients routinely
reated with drug-eluting stent implantation for ST-segment
levation myocardial infarction (STEMI). Intracoronary thrombus
urden was angiographically scored before stenting using the
lassification in 5 grades previously described by Gibson et al. (2).
ecause a majority of patients suffering an acute STEMI present
ith an occluded IRA that precludes any thrombus classification,
he investigators proposed to reclassify thrombus burden after flow
estoration was obtained by a minimal intervention based on the
se of a guidewire crossing or small (diameter 1.5 mm) deflated
alloon passage or dilation. It would have been interesting to know
he level of flow achievement based on Thrombosis In Myocardial
nfarction (TIMI) flow grade obtained by minimal intervention
mong patients with totally occluded IRA in the study of Sianostenting has been previously proposed for direct reperfusion of
atients with acute STEMI (3). In their study (1), the investigators
ound that a large thrombus burden is an independent predictor of
ong-term mortality. Analysis of Table 1 shows (1), however, that
hen compared with patients with a small thrombus burden,
atients with a large thrombus burden had higher rates of use of
ntra-aortic balloon pump and inotropes, and they more frequently
ad diabetes mellitus, stent thrombosis at presentation, and pace-
aker implantation. Also, although it is widely recognized as a
ajor predictor of clinical outcome in patients with STEMI, left
entricular ejection fraction has not been reported in the study by
ianos et al. (1). Entering all of these additional variables into the
ultivariate analysis model might have changed the results pre-
ented in their Table 3 (1) regarding the independent role of
hrombus burden for 2-year mortality. The results of the study by
ianos et al. (1) regarding procedural outcome (Table 4 in their
rticle) support the hypothesis and the data of a previously
ublished work (3), in which it was suggested that immediate
tenting should probably be avoided in many patients in the
cute phase of STEMI once flow has been restored using
inimalist intervention. Therefore, there is a need for a
andomized trial in which the classical approach of direct
ercutaneous intervention with immediate stenting would be
ompared with stent implantation strategy based on thrombus
urden analysis after flow restoration by immediate minimalist
ntervention.
